α-Lipoic acid is amphipathic with low molecular sulphur-containing fatty acid and has strong antioxidant effects. It has been used at the purposes of anti-ageing, treatment of diabetic neuropathy, and supplement as antioxidant. Though α-lipoic acid is normally administered in oral or injection, it has not been used in a topical use via skin because of its bad penetration. We developed the novel nanocapsule of α-lipoic acid, named α-lipoactive (nLA), to improve skin permeability. The nLA is constructed as micelles of α-lipoic acid mixed with the non-ionic surfactant, and its surface of the micelles was coated with inorganic metal salts. It is water soluble and has a diameter of approximately 8-15 nm. After nLA was applied to the murine skin, epidermal thickening was observed. It was confirmed that this effect is caused by α-lipoic acid molecule, but not by the raw material used for encapsulation. In in vivo experiments, it was found that nLA is very effective for improving UV-induced pigmentation and epidermal thickening. Our findings suggest that nanoencapsulation of α-lipoic acid is considerably effective for topical application.
| INTRODUC TI ON
α-Lipoic acid is a sulphur-containing, low molecular weight fatty acid.
It is known to be a coenzyme of dihydrolipoate acyltransferase in mitochondrial tricarboxylic acid cycle. Within a cell, the thiols of α-lipoic acid are reduced immediately and exist in the reduced form. [1] α-Lipoic acid has various biological activities besides the function as a coenzyme and acts as a suppressor of AMP-activated protein kinase in the signalling pathway in adipocyte and inhibits uptake and accumulation of lipids into the cell. [2] In addition, it is known that α-lipoic acid improves blood glucose level by increasing glucose uptake into the muscle, and it is applied for the treatment of diabetes. [3] Moreover, it possesses strong antioxidant properties [1] and has been used as a medicine or supplement of anti-ageing by injection or an oral administration. In recent years, in the field of cosmetics and cosmetic dermatology, development of an effective novel materials available for supplements and/or drugs for skin anti-ageing is strongly expected. [4, 5] Most of them are administered by perioral or intravenous injection. Due to two major problems, the pharmacological effect of α-lipoic acid for anti-ageing was not sufficient. First, it was reported that α-lipoic acid administered orally or intravenously was removed by liver from the blood within 30 minutes. [6, 7] Second, since the skin has a high barrier function, penetration of α-lipoic acid by topical administration from the skin must be very low. [8] Accepted: 25 October 2018 DOI: 10.1111/exd.13828
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Therefore, it is considered that the antioxidant effect of α-lipoic acid was not sufficiently exhibited. [9] Various studies for improvement of skin permeability have been reported. An emulsion and micelle have been used for effective percutaneous absorption. [10] We previously developed retinoic acid nanoparticles (atRA) coated with inorganic salts on the spherical micelle surface of atRA. [11] Thereby, more effective improvement of pigmentation by encapsulated atRA via the topical application on the skin than that by non-capsulated naked atRA was reported. [12, 13] These effects were derived from sustainedrelease due to encapsulation, and the effective percutaneous absorption by surface structure of capsule. We developed the nanocapsule of the α-lipoic acid to investigate its pharmacological effect on skin. Both atRA and α-lipoic acid have similar molecular weight (the molecular weight is 300.44 and 206.33, respectively) and amphiphilic properties (because of fatty acid with carboxylic function).
Therefore, α-lipoic acid was also encapsulated in the same way as atRA nanocapsule. [11] Yellow α-lipoic acid powder was completely covered with an inorganic thin film and was named as α-lipoactive (nLA). This nanocapsule was expected to improve skin permeability of α-lipoic acid and its sustained-release like that observed in atRA nanocapsule. Some antioxidant molecules show inhibitory effect on pigmentation, and the mechanism is reported to be antioxidant dependent. [14] Since α-lipoic acid is known an antioxidant, we expected the preventive effect of nLA on pigmentation. However, in vivo experiment, preventive effect was scarcely observed (data not shown).
However, we found that α-lipoic acid promotes the metabolism of the epidermal layer leading to reduction of pigmentation. In the present study, we report the details of increased keratinocyte metabolism by nLA in vivo experiments. Nanoencapsulation of α-lipoic acids is expected to be a new and highly effective drugs for antiageing in medical and/or cosmetic fields.
| MATERIAL S AND ME THODS

| Materials
(R/S)-lipoic acid (α-lipoic acid, LA) was purchased from Tateyama Kasei Co., Ltd (Toyama, Japan). Non-ionic surfactant of stearyl poly (20) oxyethylene ether (BS-20) was purchased from Nikko Chemicals Co., Ltd (Tokyo, Japan). 4-(2-hydroxyethyl)-1-piperazineethanesulfo nic acid (HEPES), sodium hydride, calcium chloride, magnesium chloride and sodium carbonate were commercially obtained from Wako Pure Chemicals Industries Ltd (Osaka, Japan). All other chemicals were of the highest commercially available grade.
| Preparation of α-lipoic acid nanocapsules (nLA)
Nanocapsule of retinoic acid (atRA) was used as reference for capsulation of LA. [11, 12] 3.00 g LA was dissolved in 57 mL 0.26 mol/L sodium hydroxide solution and poured in 15 mL deionized water.
Further, to make the mixed micelles, 15 g BS-20 was dissolved and mixed. LA molecules become water soluble and form mixed micelles with surfactants in this solution. pH of this mixed solution was then adjusted to 5.5 using 5 N hydrochloric acid; 2.88 mL of 2.5 mol/L MgCl 2 was added and could mix for 12 hours. Furthermore, after adding 2.88 mL of 1 mol/L NaCO 3 and mixing for 12 hours, deionized water was added, and the scalpel rise was performed at 100 mL.
This was set to 3% α-Lipoactive (nLA). nLA was confirmed and analysed by small angle X-rat scattering (SAXS) and dynamic light scattering (DLS). The methods of SAXS and DLS were similar to that used in our previous study. [11] Three percent LA solution: 3.00 g LA dissolved in 116 mL 1M NaOH solution, 2.38 g HEPES was added, and scalpel rise was performed at 100 mL. All LA solutions were prepared just before the use in a dark place that blocked the light and stored at room temperature.
atRA nanocapsules were performed as described by Yamaguchi et al. [11] 
| Topical application of nLA in mice
Five-week-old hairless mice were purchased from Japan SLC, Inc.
(Shizuoka, Japan), and were cured in the facility for 1 week. Each drug (45 mg) was applied once a day on dorsal area (2 × 3 cm 2 , n = 3) of each mouse, and its application was done five times per week. 
| Time course analysis of gene expression
In genetic analysis, male 5-week-old hairless mice were used. Each drug was applied to dorsal surface of mice (2 × 3 cm 2 , n = 3), and 45 mg was applied each time. The skin tissues were obtained at 0, 1 and 3 days. Total RNA was prepared as described by Yamaguchi et al. [12] Gene expression of growth factors was analysed using quantitative real-time PCR system (Thermo Fisher Scientific, Inc.,
Waltham, Massachusetts, USA). We used primer sets 5′-CATGGCC TTCCGTGTTCCTA-3′/5′-GCGGCACGTCAGATCCA-3′, GAPDH; 5′-TCTTTCTGGCCGCAGTGTT-3′/5′-GAAGCCGCTCCAGACTCTCA-3 ′, HB-EGF; 5′-GGACTCGGAAGCAGCTATCAA-3′/5′-TCCGCTTGGC TCATCACA-3′, EGF; 5′-CGGACAGCTCGCTCTGCTA-3′/5′-TCCAGA GCCTGGCACACA-3′, TGF-α; and 5′-AAGGGACCCAGGAGATGAAG A-3′/5′-CAACTGCCACGGTCCTGAT-3′, FGF-7. GAPDH was used as housekeeping gene for normalization.
| Immunostaining analysis of epidermis differentiation
Paraffin-embedded sections (4 μm) were retrieved by 0.2% pepsin and then incubated over night with antimouse loricrin ( 
| RE SULTS
| Nanoencapsulation of α-lipoic acid
The schematic preparation procedure of α-lipoic acid nanocapsule is shown in Figure 1A . Novel nanoencapsulation was performed by the template method in which the mixed micelle of α-lipoic acid (LA) and the non-ionic surfactant would be coated with divalent metal anion (magnesium or calcium ion), and the bicarbonate ions as inorganic salts. Hereafter, we refer to this nanocapsule of LA as α-lipoactive (nLA). The average hydrodynamic diameter of the nLA was measured by dynamic light scattering method; it was approximately 8-15 nm (data not shown).
| nLA stimulates the proliferation of keratinocytes by topical application
In this experiment, the effectiveness of nLA was tested using a hairless mouse. Hairless mice tend to have lower permeability of drugs and other chemicals through the skin than hairy mice. The reason is thought to be high barrier function due to lack of hair follicles which is similar to human skin with fewer hairs. Similarly, hairless mice were used for permeability experiments of nLA. Studies on skin permeability of nLA were conducted using the Franz cell method. As a result, it became clear that the permeability to the skin was clearly higher than that of LA alone. [15] In vivo studies, pharmacological effects of nLA on the skin were analysed using a hairless mouse. Hairless mice tend to have lower permeability of drugs and the like through the skin than hairy mice. The reason is thought to be high barrier function because there is no hair on the skin. This point is assumed to be close to human skin with less body hair. Similarly, hairless mice were used for permeability experiments of nLA.
Encapsulation of LA can produce up to 3wt% LA concentration, but as an initial study of pharmacological effects, we decided to verify the effect of nLA on skin at 1wt%. The nLA capsules correspond to 1wt% of LA, and the subcutaneous treatment on the dorsal areas of hairless mice was performed five times in a week.
Significant changes during the experiment were not observed with the appearance of the dorsal region such as corneal abrasion and redness. In the tissue observation, the epidermal layer was significantly thickened by application of 1wt% nLA compared with negative control of distilled water (DW) application. After application of 1wt% LA, significant change was not observed in the skin thickness ( Figure 1B,C) . Further, we considered that the thickened epidermal layer might be caused by the promotion of proliferation of a keratinocyte. Immunostaining using Ki-67 antibody was performed to investigate the cell division rates in epidermal layer ( Figure 1D ,E).
As a result, significant increase in the number of Ki-67-positive cells was observed after 1wt% nLA application, compared with that after DW application (P < 0.01). Otherwise, no marked change was To investigate the influence of each component for nanoencapsulation, not only the tissue observation but also the expression of the Ki -67 protein was observed. Figure 2 shows that there is no effect of surfactant and/or inorganic salts on activation of epidermal layer.
In addition, it was also found that keratinocytes are activated with increasing concentrations of LA. The results of this study revealed that nanocapsulated LA significantly stimulates keratinocytes than naked LA.
| Analysis of gene expression of keratinocyte growth factors
To analyse the proliferation activity of the keratinocytes by nLA application, single dose application of nLA was performed in vivo experiment with the passage of time. Since it is a single application, it was judged that it is difficult to detect fluctuating mRNA accurately at low concentrations of nLA or LA, and therefore, it was experimented with the highest concentration of 3%. First, the temporal change of epidermal hyperplasia was analysed ( Figure 3A ).
Comparison of LA and nLA revealed that the epidermal layer became the thickest on the 3rd day after application by nanoencapsulation. 
| Nanocapsules improve ultraviolet (UV)-induced pigmentation
Keratinocytes carrying melanin pigment in cells move to the upper layer of epidermis while differentiating. It eventually becomes corneocytes and peels off, and melanin pigment is also discharged. It is already known that turnover acceleration of the epidermis layer leads to improvement of pigmentation. All-trans retinoic acid (atRA)
is famous as a representative drug. [16] nLA promotes the proliferation of keratinocytes after topical application in mice. Therefore, we anticipated that nLA should improve UV-induced pigmentation cured by epidermal layer metabolism. Guinea pigs, which were heavily F I G U R E 1 Schematic representation of the nanoencapsulation of α-lipoic acid and its skin permeability analysis. A, Preparation process of α-lipoactive (nLA). α-Lipoic acid (LA) is dissolved in aqueous sodium hydroxide. LA is amphipathic and forms mixed micelles with nonionic surfactants (left). The magnesium/calcium ion is a divalent metal ion, which binds to the carbonyl group of LA and further binds the bicarbonate ion, and as a result, an inorganic salt is formed. As a result, surface of the nanocapsule of LA would be coated with magnesium/ calcium carbonate. Proliferation of epidermal keratinocyte by topical application of nLA. The atRA nanocapsule and DW were applied as positive and negative control. B, H & E staining for histological analysis in mouse skin. Scale bar = 100 μm. C, The thickness of epidermal layer of mouse skin. The thickness was measured from the H & E staining microscopic photograph. D, The Ki-67 antibody immunostaining of the mouse skin tissue. Scale bar = 50 μm. E, The rate of Ki-67 immunostaining positive cells in a basal cell layer. The positive cells were counted from the image of Ki-67 immunostaining. Data were presented as mean ± SD. Statistically significant difference was reported † P < 0.01 and ‡ P < 0.001 
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All nLA groups, as compared with LA group, showed significant improvement in the ΔL* value after 11 days. Particularly, LA having a concentration of 1.00 wt.% or more in the nanocapsules showed remarkable effect after 9 days of application.
On the other hand, corneal abrasion and slight erythema (raised a * value indicating reddish) were observed in nLA with LA concentration of 3%. Corneal abrasion is known to be observed when metabolism of the epidermal layer is over-accelerated and is often caused by inflammation. [17] As mentioned in Figure 2 , it was revealed that components other than lipoic acid used for nanoencapsulation are hardly involved in epidermal hyperplasia. Based on the results, it is suggested that the dose of desquamation at the early stage observed with nLA 3% application has a large influence on dose. In nLA 0.01% application, side effects including desquamation findings were not observed, and slight desquamation was observed in 1%, so safety was expected to be determined by dose. Since this experiment is continuous application, the dosage threshold for safety should be considered low compared to single application. One of the side effects is inflammation, but inflammation is known to induce pigmentation. Therefore, in the case of high concentration of LA, there is a possibility that pigmentation formation due to inflammation and competition of pigment emissions due to epidermal thickening may have occurred. Therefore, even when LA which is low concentration has a slight epidermal hypertrophy, pigmentation improvement may have been observed.
Based on the above results, skin tissue analysis of the application site was performed ( Figure 4C ). In the nLA containing 1% or more of LA, remarkable epidermal layer thickening was observed (P < 0.001 or P < 0.05). Therefore, it was suggested that marked pigmentation improvement by nLA is based on notable epidermal hyperplasia. was applied, twice a day, three to five times in a week and for two consecutive weeks. B, Changes in the ΔL* values of applied area with the passage of time. The white triangle means the day of the drugs applied. C, Comparison of thickness of epidermal layer on the 11th day. Epidermal thickness was determined on H & E stained sections. Data were presented as mean ± SD. Statistically significant difference was reported *P < 0.05, † P < 0.01 and ‡ P < 0.001
As a detailed analysis, gene expression expressed in the thickened epidermal layer was analysed. For detailed analysis of pigmentation improvement, experiments were carried out using hairless mice which are subjected to gene sequence analysis in detail. This analysis was carried out on the premise that the results in guinea pigs are probably similar in mice.
Hairless mouse dorsal skins, which was continuously applied with nLA for 5 days, were collected, and immunostaining of differentiation markers keratin 5 (K5), keratin 1 (K1) and Loricrin (Lor) was performed ( Figure S1 ). In Figure 4 , both 1% and 3% nLA had a high effect of improving pigmentation but desquamation of side effects was observed on 4th day after application at 3%, so that the results of 1% tissue analysis were verified in Figure S1 .
As a result, it was observed that K1, which is a differentiation marker of spinous and granular cells, was most strongly expressed. In comparison with atRA, nLA showed little immature keratinization (leading to corneal abrasion); no decrease in K5 expression, a differentiation marker of basal cells, was observed.
Rather, an increase in basal cell population was observed after nLA application.
From these results, it was found that application of nanoencapsulated nLA promotes the proliferation and differentiation of keratinocytes as compared with the application of atRA; therefore, it was shown that this nanoencapsulation promotes a high pigmentationimproving effect despite less irritation.
| D ISCUSS I ON
In this study, we have shown that the nanoencapsulation method is an effective means to improve the therapeutic effect of pigmentation. Simultaneously, we found that α-LA promotes differentiation and proliferation of keratinocytes rather than acting as an antioxidant.
Attempts for topical application of LA have been considered difficult due to scientific instability as a formulation and low permeability from the skin. [8] Therefore, many LA formulation studies have chosen oral administration or pulse administration as the administration route. With oral or intravenous administration, it was very difficult to find out the effectiveness of LA, because the body clearance of LA is very fast. [6, 7, 9] Since LA has chemical structure and molecular weight similar to that of all-trans retinoic acid (atRA), wrinkle and pigmentation improvement effect was expected. We have already succeeded in nanoencapsulation of atRA and found that nanoencapsulation improves pigmentation improvement even more than naked agent. [12, 13] LA can be nanoencapsulated like atRA, the effect of improving pigmentation of nLA was verified, and the detailed mechanism was confirmed by tissue analysis.
As a result, it showed a pharmacological effect like that of atRA ( Figure 4 ). LA showed inflammatory findings due to atRA external application and no suppression of basal cell proliferation ( Figure   S1 ). The pharmacological effect of pigmentation is like atRA, but the mechanism seems to be different. It has reported that atRA represses the expression of K5 in vitro. [18] The promoter region of K5 has an activator protein-1 (AP-1) response-element. [19] Retinoic acid receptor (RAR) and/or retinoid X receptor (RXR) interact with AP-1, and then these complexes bind to the promoter region and repress the transcription from K5 promoter. [20] However, since down-regulation of K5 was not observed from the tissue coated with nLA, it can be assumed that it probably does not signal through the receptor of RAR or RXR. It is unclear whether α-LA acts via the RAR.
We analysed the expression levels of several growth factors for keratinocyte proliferation in Figure 3 . It was known that LA modulates cell growth through the signal cascade of mitogenactivated protein kinase (MAPK) in various cells. [21, 22] LA regulates metabolism or differentiation via MAPK pathway and transcription factors. [2, 23] Epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor and interacts with ligand proteins, such as EGF, HB-EGF and TGF-α. [24] EGFR activates signal transduction and controls the gene expression of keratinocyte growth factors. [24, 25] From these findings, we infer that LA may participate in protein kinase signal transduction in keratinocytes. After the activation of kinase, it is considered that EGFR was immediately activated, and the expression of keratinocytes growth factor was induced. As a result, we believe that the epidermal layer thickened, and pigmentation improved.
The material which possesses antioxidant capacity is frequently used in regulation of pigmentation. This molecule suppresses inflammation by reducing active oxygen produced by ultraviolet irradiation and consequently suppresses melanin production. [14, 26] Our experiment does not irradiate any ultraviolet rays after forming pigmentation on the back of the guinea pig. Therefore, it is assumed that improvement of pigmentation in this experiment is due to pigment emission from the epidermal layer, not inhibition of pigment production.
Although LA is known as an antioxidant substance, in this experiment it is due to the emission effect rather than suppression of pigment production.
We demonstrated new effects of LA in vivo study. Since the mechanism and biochemical functions of nLA in skin were unclear, it is essential to investigate the signal transduction factors in keratinocyte. As future research, it is also important to analyse the detailed analysis of bioavailability and the in vivo dynamics of nanocapsulated LA (nLA).
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